AstraZeneca’s neuroscience Innovative Medicines Unit (iMed) has acquired a portfolio of preclinical and clinical-stage neuroscience candidates that target the enzyme farnesyltransferase and modulate autophagy from Link Medicine. In a separate deal, AstraZeneca has established an Alzheimer’s disease research alliance with four academic research laboratories to study the role of the apolipoprotein E4 (ApoE) genotype. The company adopted a virtual neuroscience R&D model in February 2012.